Advances in gene therapy for neurogenetic diseases: a brief review

Neurogenetic diseases are neurological conditions with a genetic cause (s). There are thousands of neurogenetic diseases, and most of them are incurable. The development of bioinformatics and elucidation of the mechanism of pathogenesis have allowed the development of gene therapy approaches, which...

Full description

Saved in:

Bibliographic Details
Published in	Journal of molecular medicine (Berlin, Germany) Vol. 100; no. 3; pp. 385 - 394
Main Authors	Xie, Ying-Xuan, Lv, Wen-Qi, Chen, Yi-Kun, Hong, Shunyan, Yao, Xiang-Ping, Chen, Wan-Jin, Zhao, Miao
Format	Journal Article
Language	English
Published	Berlin/Heidelberg Springer Berlin Heidelberg 01.03.2022 Springer Nature B.V
Subjects	Antisense oligonucleotides Antisense RNA Bioinformatics Biomedical and Life Sciences Biomedicine Expression vectors Gene therapy Genome editing Human Genetics Internal Medicine Molecular Medicine Review RNA editing RNA-mediated interference Antisense oligonucleotides (ASOs) Gene therapy Neurogenetic diseases Gene editing
Online Access	Get full text

Cover

Loading…

Abstract	Neurogenetic diseases are neurological conditions with a genetic cause (s). There are thousands of neurogenetic diseases, and most of them are incurable. The development of bioinformatics and elucidation of the mechanism of pathogenesis have allowed the development of gene therapy approaches, which show great potential in treating neurogenetic diseases. Viral vectors delivery, antisense oligonucleotides, gene editing, RNA interference, and burgeoning viroid delivery technique are promising gene therapy strategies, and commendable therapeutic effects in the treatment of neurogenetic diseases have been achieved (Fig. 1 ). This review highlights a sampling of advances in gene therapies for neurogenetic disorders. Fig. 1 Examples of gene therapy strategies used in the treatment of neurogenetic diseases. The schematic diagram shows different gene therapy approaches used for treating a sampling of neurogenetic disorders, such as ASO therapy, gene editing, gene augmentation, and RNA interference
AbstractList	Neurogenetic diseases are neurological conditions with a genetic cause (s). There are thousands of neurogenetic diseases, and most of them are incurable. The development of bioinformatics and elucidation of the mechanism of pathogenesis have allowed the development of gene therapy approaches, which show great potential in treating neurogenetic diseases. Viral vectors delivery, antisense oligonucleotides, gene editing, RNA interference, and burgeoning viroid delivery technique are promising gene therapy strategies, and commendable therapeutic effects in the treatment of neurogenetic diseases have been achieved (Fig. 1). This review highlights a sampling of advances in gene therapies for neurogenetic disorders. Fig. 1 Examples of gene therapy strategies used in the treatment of neurogenetic diseases. The schematic diagram shows different gene therapy approaches used for treating a sampling of neurogenetic disorders, such as ASO therapy, gene editing, gene augmentation, and RNA interference.Neurogenetic diseases are neurological conditions with a genetic cause (s). There are thousands of neurogenetic diseases, and most of them are incurable. The development of bioinformatics and elucidation of the mechanism of pathogenesis have allowed the development of gene therapy approaches, which show great potential in treating neurogenetic diseases. Viral vectors delivery, antisense oligonucleotides, gene editing, RNA interference, and burgeoning viroid delivery technique are promising gene therapy strategies, and commendable therapeutic effects in the treatment of neurogenetic diseases have been achieved (Fig. 1). This review highlights a sampling of advances in gene therapies for neurogenetic disorders. Fig. 1 Examples of gene therapy strategies used in the treatment of neurogenetic diseases. The schematic diagram shows different gene therapy approaches used for treating a sampling of neurogenetic disorders, such as ASO therapy, gene editing, gene augmentation, and RNA interference. Neurogenetic diseases are neurological conditions with a genetic cause (s). There are thousands of neurogenetic diseases, and most of them are incurable. The development of bioinformatics and elucidation of the mechanism of pathogenesis have allowed the development of gene therapy approaches, which show great potential in treating neurogenetic diseases. Viral vectors delivery, antisense oligonucleotides, gene editing, RNA interference, and burgeoning viroid delivery technique are promising gene therapy strategies, and commendable therapeutic effects in the treatment of neurogenetic diseases have been achieved (Fig. 1 ). This review highlights a sampling of advances in gene therapies for neurogenetic disorders. Fig. 1 Examples of gene therapy strategies used in the treatment of neurogenetic diseases. The schematic diagram shows different gene therapy approaches used for treating a sampling of neurogenetic disorders, such as ASO therapy, gene editing, gene augmentation, and RNA interference Neurogenetic diseases are neurological conditions with a genetic cause (s). There are thousands of neurogenetic diseases, and most of them are incurable. The development of bioinformatics and elucidation of the mechanism of pathogenesis have allowed the development of gene therapy approaches, which show great potential in treating neurogenetic diseases. Viral vectors delivery, antisense oligonucleotides, gene editing, RNA interference, and burgeoning viroid delivery technique are promising gene therapy strategies, and commendable therapeutic effects in the treatment of neurogenetic diseases have been achieved (Fig. 1). This review highlights a sampling of advances in gene therapies for neurogenetic disorders. Neurogenetic diseases are neurological conditions with a genetic cause (s). There are thousands of neurogenetic diseases, and most of them are incurable. The development of bioinformatics and elucidation of the mechanism of pathogenesis have allowed the development of gene therapy approaches, which show great potential in treating neurogenetic diseases. Viral vectors delivery, antisense oligonucleotides, gene editing, RNA interference, and burgeoning viroid delivery technique are promising gene therapy strategies, and commendable therapeutic effects in the treatment of neurogenetic diseases have been achieved (Fig. 1). This review highlights a sampling of advances in gene therapies for neurogenetic disorders. Fig. 1 Examples of gene therapy strategies used in the treatment of neurogenetic diseases. The schematic diagram shows different gene therapy approaches used for treating a sampling of neurogenetic disorders, such as ASO therapy, gene editing, gene augmentation, and RNA interference.
Author	Yao, Xiang-Ping Chen, Yi-Kun Lv, Wen-Qi Hong, Shunyan Chen, Wan-Jin Zhao, Miao Xie, Ying-Xuan
Author_xml	– sequence: 1 givenname: Ying-Xuan orcidid: 0000-0001-6893-8466 surname: Xie fullname: Xie, Ying-Xuan organization: Department of Neurology, Institute of Neuroscience, Fujian Key Laboratory of Molecular Neurology, the First Affiliated Hospital, Fujian Medical University – sequence: 2 givenname: Wen-Qi surname: Lv fullname: Lv, Wen-Qi organization: Department of Neurology, Institute of Neuroscience, Fujian Key Laboratory of Molecular Neurology, the First Affiliated Hospital, Fujian Medical University – sequence: 3 givenname: Yi-Kun surname: Chen fullname: Chen, Yi-Kun organization: Department of Neurology, Institute of Neuroscience, Fujian Key Laboratory of Molecular Neurology, the First Affiliated Hospital, Fujian Medical University – sequence: 4 givenname: Shunyan surname: Hong fullname: Hong, Shunyan organization: Department of Neurology, Institute of Neuroscience, Fujian Key Laboratory of Molecular Neurology, the First Affiliated Hospital, Fujian Medical University – sequence: 5 givenname: Xiang-Ping surname: Yao fullname: Yao, Xiang-Ping organization: Department of Neurology, Institute of Neuroscience, Fujian Key Laboratory of Molecular Neurology, the First Affiliated Hospital, Fujian Medical University – sequence: 6 givenname: Wan-Jin orcidid: 0000-0002-9472-8494 surname: Chen fullname: Chen, Wan-Jin organization: Department of Neurology, Institute of Neuroscience, Fujian Key Laboratory of Molecular Neurology, the First Affiliated Hospital, Fujian Medical University – sequence: 7 givenname: Miao orcidid: 0000-0003-4425-5294 surname: Zhao fullname: Zhao, Miao email: zhaomiao91@fjmu.edu.cn organization: Department of Neurology, Institute of Neuroscience, Fujian Key Laboratory of Molecular Neurology, the First Affiliated Hospital, Fujian Medical University
BackLink	https://www.ncbi.nlm.nih.gov/pubmed/34837498$$D View this record in MEDLINE/PubMed
BookMark	eNp9kU1LHTEUhkNR6lX7B7ooATfdTD35mCTjTqVfILjRdchkTjRyb-Y2mVHuvze311pw4SIcCM-THN73kOylMSEhnxl8YwD6tAAw6BrgbHuUbjYfyIJJwRsmJeyRBXRSNVwzdUAOS3mouG47-ZEcCGmElp1ZkIvz4dElj4XGRO8wIZ3uMbv1hoYx04RzHre3U_R0iAVdwXJGHe1zxEAzPkZ8Oib7wS0LfnqZR-T2x_eby1_N1fXP35fnV40Xup2aoAVvB2VabGGQQnrPuNEdaMd6NO0QlPBdr51XwhmnvPcBggp9G7QZ2oGJI_J19-46j39mLJNdxeJxuXQJx7lYrkACB8F0RU_eoA_jnFPdrlLcSBA1lUp9eaHmfoWDXee4cnlj_6VTAb4DfB5LyRheEQZ2W4HdVWBr_PZvBXZTJfNG8nFyUxzTlF1cvq-KnVrqP-kO8_-137GeAZk6md4
CitedBy_id	crossref_primary_10_1111_imj_16103 crossref_primary_10_3390_biology12121459 crossref_primary_10_1016_j_jaac_2024_01_015 crossref_primary_10_1016_j_neurot_2024_e00427
Cites_doi	10.1016/S0140-6736(16)31408-8 10.1016/j.cell.2018.02.033 10.1016/j.drudis.2017.01.013 10.1056/NEJMoa2003715 10.1053/j.semperi.2018.09.003 10.1038/mt.2015.50 10.1126/science.aad5177 10.1038/s41422-019-0165-4 10.1038/s41586-019-1711-4 10.1073/pnas.240335297 10.1126/science.aaq0180 10.1038/s41586-019-1314-0 10.1038/s41587-020-00781-8 10.1038/s41588-020-0623-4 10.1056/NEJMoa1706198 10.1016/j.cmet.2018.03.004 10.1136/jnnp-2017-317412 10.1001/jamaneurol.2020.1484 10.1016/j.molcel.2019.09.013 10.1016/S1474-4422(21)00071-5 10.1016/S0140-6736(13)61939-X 10.1101/gad.1941310 10.1038/s41551-019-0357-8 10.1021/acsami.6b10146 10.1038/s41587-019-0205-0 10.1074/jbc.274.40.28270 10.1038/s41467-018-08224-4 10.1038/ncomms16105 10.1016/j.pharmthera.2019.107453 10.1001/archneurol.2011.74 10.1016/j.neuron.2007.02.020 10.1038/nm1205 10.1371/journal.pbio.0050073 10.1089/ard.1993.3.383 10.1016/S1474-4422(09)70272-8 10.1038/mtna.2016.58 10.1038/nature26155 10.1016/j.cell.2020.03.024 10.1089/hum.2018.021 10.1016/j.ymthe.2020.01.001 10.1016/j.braindev.2017.03.024 10.1016/j.cell.2015.09.038 10.1212/WNL.0000000000005680 10.1056/NEJMoa1700554 10.1038/d41586-021-01177-7 10.1038/nature13769 10.1126/science.aav9973 10.1038/s41422-020-0304-y 10.1016/S1474-4422(04)00678-7 10.1146/annurev-pathmechdis-012418-012857 10.1002/jcp.27972 10.1126/science.aaw7166 10.1056/NEJMoa1702752 10.1038/s41587-019-0236-6 10.1073/pnas.0501507102 10.1016/S1474-4422(13)70061-9 10.1038/s41587-020-0561-9 10.1016/j.biotechadv.2017.11.008 10.1038/s41551-020-00656-y 10.1146/annurev-med-041217-010829 10.1016/j.ejpb.2017.11.010 10.1016/j.neuropharm.2016.02.013 10.1002/cpmo.58 10.1038/nbt.4148 10.1136/jmedgenet-2014-102968 10.1056/NEJMoa1900907 10.1093/nsr/nwz131 10.1146/annurev-pharmtox-010919-023738 10.1016/j.ymthe.2020.01.005 10.1038/nature19802 10.1038/352815a0 10.1038/nrendo.2016.90 10.1016/j.ymthe.2019.12.010 10.1038/s41591-018-0204-6 10.1038/nmat3765 10.1007/s12035-014-8724-7 10.1186/1750-1172-7-51 10.1042/BJ20120146 10.1126/science.aaf5573 10.1126/science.1171242 10.2147/DDDT.S97635
ContentType	Journal Article
Copyright	The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature 2021 2021. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature 2021.
Copyright_xml	– notice: The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature 2021 – notice: 2021. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature. – notice: The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature 2021.
DBID	AAYXX CITATION NPM 3V. 7TK 7X7 7XB 88E 8AO 8FI 8FJ 8FK ABUWG AFKRA BENPR CCPQU FYUFA GHDGH K9. M0S M1P PHGZM PHGZT PJZUB PKEHL PPXIY PQEST PQQKQ PQUKI PRINS 7X8
DOI	10.1007/s00109-021-02167-y
DatabaseName	CrossRef PubMed ProQuest Central (Corporate) Neurosciences Abstracts Health & Medical Collection ProQuest Central (purchase pre-March 2016) Medical Database (Alumni Edition) ProQuest Pharma Collection Hospital Premium Collection Hospital Premium Collection (Alumni Edition) ProQuest Central (Alumni) (purchase pre-March 2016) ProQuest Central (Alumni) ProQuest Central UK/Ireland ProQuest Central ProQuest One Community College Health Research Premium Collection Health Research Premium Collection (Alumni) ProQuest Health & Medical Complete (Alumni) ProQuest Health & Medical Collection Proquest Medical Database ProQuest Central Premium ProQuest One Academic ProQuest Health & Medical Research Collection ProQuest One Academic Middle East (New) ProQuest One Health & Nursing ProQuest One Academic Eastern Edition (DO NOT USE) ProQuest One Academic ProQuest One Academic UKI Edition ProQuest Central China MEDLINE - Academic
DatabaseTitle	CrossRef PubMed ProQuest One Academic Middle East (New) ProQuest Health & Medical Complete (Alumni) ProQuest Central (Alumni Edition) ProQuest One Community College ProQuest One Health & Nursing ProQuest Pharma Collection ProQuest Central China ProQuest Central ProQuest Health & Medical Research Collection Health Research Premium Collection Health and Medicine Complete (Alumni Edition) Health & Medical Research Collection ProQuest Central (New) ProQuest Medical Library (Alumni) ProQuest One Academic Eastern Edition ProQuest Hospital Collection Health Research Premium Collection (Alumni) Neurosciences Abstracts ProQuest Hospital Collection (Alumni) ProQuest Health & Medical Complete ProQuest Medical Library ProQuest One Academic UKI Edition ProQuest One Academic ProQuest One Academic (New) ProQuest Central (Alumni) MEDLINE - Academic
DatabaseTitleList	MEDLINE - Academic ProQuest One Academic Middle East (New) PubMed
Database_xml	– sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: BENPR name: ProQuest Central url: https://www.proquest.com/central sourceTypes: Aggregation Database
DeliveryMethod	fulltext_linktorsrc
Discipline	Medicine
EISSN	1432-1440
EndPage	394
ExternalDocumentID	34837498 10_1007_s00109_021_02167_y
Genre	Research Support, Non-U.S. Gov't Journal Article Review
GrantInformation_xml	– fundername: National Natural Science Foundation of China grantid: 82025012; U1905210; 82171841 funderid: http://dx.doi.org/10.13039/501100001809 – fundername: Natural Science Foundation of Fujian Province grantid: 2019J02010; 2021J01221 funderid: http://dx.doi.org/10.13039/501100003392 – fundername: the Startup Fund for Scientific Research of Fujian Medical University grantid: 2018QH2035 – fundername: Scientific Research Foundation for the introduction of talent of the First Affiliated Hospital of Fujian Medical University – fundername: Post-doctoral Startup Fund for Scientific Research of the First Affiliated Hospital of Fujian Medical University grantid: BSH3606
GroupedDBID	--- -4W -56 -5G -BR -EM -Y2 -~C .55 .86 .VR 06C 06D 0R~ 0VY 199 1N0 2.D 203 28- 29L 29~ 2J2 2JN 2JY 2KG 2KM 2LR 2P1 2VQ 2~H 30V 36B 3O- 3SX 3V. 4.4 406 408 409 40D 40E 53G 5GY 5QI 5RE 5VS 67N 67Z 6NX 78A 7X7 88E 8AO 8FI 8FJ 8TC 8UJ 95- 95. 95~ 96X AAAVM AABHQ AACDK AAHNG AAIAL AAJBT AAJKR AANXM AANZL AARHV AARTL AASML AATNV AATVU AAUYE AAWCG AAYIU AAYQN AAYTO AAYZH ABAKF ABBBX ABBXA ABDZT ABECU ABFTV ABHLI ABHQN ABJNI ABJOX ABKCH ABKTR ABLJU ABMNI ABMQK ABNWP ABOCM ABPLI ABQBU ABQSL ABSXP ABTEG ABTHY ABTKH ABTMW ABULA ABUWG ABWNU ABXPI ACAOD ACBXY ACDTI ACGFS ACHSB ACHXU ACIWK ACKNC ACMDZ ACMLO ACOKC ACOMO ACPIV ACPRK ACZOJ ADBBV ADHIR ADIMF ADINQ ADKNI ADKPE ADRFC ADTPH ADURQ ADYFF ADYPR ADZKW AEBTG AEFIE AEFQL AEGAL AEGNC AEJHL AEJRE AEKMD AEMSY AEOHA AEPYU AESKC AETLH AEVLU AEXYK AFEXP AFGCZ AFKRA AFLOW AFQWF AFRAH AFWTZ AFZKB AGAYW AGDGC AGGDS AGJBK AGMZJ AGQEE AGQMX AGRTI AGWIL AGWZB AGYKE AHAVH AHBYD AHKAY AHMBA AHSBF AHYZX AIAKS AIGIU AIIXL AILAN AITGF AJBLW AJRNO AJZVZ AKMHD ALIPV ALMA_UNASSIGNED_HOLDINGS ALWAN AMKLP AMXSW AMYLF AOCGG ARMRJ ASPBG AXYYD AZFZN B-. BA0 BBWZM BDATZ BENPR BGNMA BPHCQ BSONS BVXVI CAG CCPQU COF CS3 CSCUP DDRTE DL5 DNIVK DPUIP EBD EBLON EBS EIOEI EJD EMB EMOBN EN4 EPAXT ESBYG F5P FEDTE FERAY FFXSO FIGPU FINBP FNLPD FRRFC FSGXE FWDCC FYUFA G-Y G-Z GGCAI GGRSB GJIRD GNWQR GQ6 GQ7 GQ8 GXS H13 HF~ HG5 HG6 HMCUK HMJXF HQYDN HRMNR HVGLF HZ~ I09 IHE IJ- IKXTQ ITM IWAJR IXC IZIGR IZQ I~X I~Z J-C J0Z JBSCW JCJTX JZLTJ KDC KOV KOW KPH LAS LLZTM M1P M4Y MA- N2Q N9A NB0 NDZJH NPVJJ NQJWS NU0 O9- O93 O9G O9I O9J OAM P19 PF0 PQQKQ PROAC PSQYO PT4 PT5 Q2X QOK QOR QOS R89 R9I RHV RIG RNI RNS ROL RPX RRX RSV RZK S16 S1Z S26 S27 S28 S3A S3B SAP SBL SBY SCLPG SDH SDM SHX SISQX SJYHP SNE SNPRN SNX SOHCF SOJ SPISZ SRMVM SSLCW SSXJD STPWE SV3 SZN T13 T16 TSG TSK TSV TUC U2A U9L UG4 UKHRP UOJIU UTJUX UZXMN VC2 VFIZW W23 W48 WJK WK6 WK8 X7M YLTOR Z45 Z7R Z7U Z7W Z7Z Z82 Z83 Z87 Z8M Z8O Z8Q Z8T Z8V Z8W Z91 ZMTXR ZOVNA ~EX AAPKM AAYXX ABBRH ABDBE ADHKG AFDZB AFOHR AGQPQ AHPBZ ATHPR AYFIA CITATION PHGZM PHGZT NPM 7TK 7XB 8FK ABRTQ K9. PJZUB PKEHL PPXIY PQEST PQUKI PRINS 7X8
ID	FETCH-LOGICAL-c375t-f7325d685e50d434cc1287907a1be85df63c9b7ac63a8a6cccf0f6fb5f78d5d13
IEDL.DBID	U2A
ISSN	0946-2716 1432-1440
IngestDate	Fri Jul 11 15:35:41 EDT 2025 Sat Aug 16 17:20:50 EDT 2025 Thu Apr 03 06:58:49 EDT 2025 Tue Jul 01 02:55:39 EDT 2025 Thu Apr 24 23:02:18 EDT 2025 Fri Feb 21 02:47:40 EST 2025
IsPeerReviewed	true
IsScholarly	true
Issue	3
Keywords	Antisense oligonucleotides (ASOs) Gene therapy Neurogenetic diseases Gene editing
Language	English
License	2021. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature.
LinkModel	DirectLink
MergedId	FETCHMERGED-LOGICAL-c375t-f7325d685e50d434cc1287907a1be85df63c9b7ac63a8a6cccf0f6fb5f78d5d13
Notes	ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 14 ObjectType-Review-3 content type line 23
ORCID	0000-0003-4425-5294 0000-0002-9472-8494 0000-0001-6893-8466
PMID	34837498
PQID	2628403271
PQPubID	48876
PageCount	10
ParticipantIDs	proquest_miscellaneous_2604020317 proquest_journals_2628403271 pubmed_primary_34837498 crossref_primary_10_1007_s00109_021_02167_y crossref_citationtrail_10_1007_s00109_021_02167_y springer_journals_10_1007_s00109_021_02167_y
ProviderPackageCode	CITATION AAYXX
PublicationCentury	2000
PublicationDate	20220300 2022-03-00 20220301
PublicationDateYYYYMMDD	2022-03-01
PublicationDate_xml	– month: 3 year: 2022 text: 20220300
PublicationDecade	2020
PublicationPlace	Berlin/Heidelberg
PublicationPlace_xml	– name: Berlin/Heidelberg – name: Germany – name: New York
PublicationTitle	Journal of molecular medicine (Berlin, Germany)
PublicationTitleAbbrev	J Mol Med
PublicationTitleAlternate	J Mol Med (Berl)
PublicationYear	2022
Publisher	Springer Berlin Heidelberg Springer Nature B.V
Publisher_xml	– name: Springer Berlin Heidelberg – name: Springer Nature B.V
References	Engelen, de Visser, van Geel, Wanders, Aubourg, Poll-The (CR54) 2012; 7 Bennett, Kordasiewicz, Cleveland (CR2) 2021; 61 Le Guiner, Servais, Montus, Larcher, Fraysse, Moullec, Allais, François, Dutilleul, Malerba (CR49) 2017; 8 Hu, Miller, Geurts, Tang, Chen, Sun, Zeina, Gao, Rees, Lin (CR30) 2018; 556 Jin, Zong, Gao, Zhu, Wang, Qin, Liang, Wang, Qiu, Zhang (CR35) 2019; 364 CR38 Grünewald, Zhou, Iyer, Lareau, Garcia, Aryee, Joung (CR32) 2019; 37 East Seletsky, O'Connell, Knight, Burstein, Cate, Tjian, Doudna (CR40) 2016; 538 Eichler, Duncan, Musolino, Orchard, De Oliveira, Thrasher, Armant, Dansereau, Lund, Miller (CR55) 2017; 377 Shirley, de Jong, Terhorst, Herzog (CR64) 2020; 28 Mahas, Neal Stewart, Mahfouz (CR39) 2018; 36 Bennett (CR6) 2019; 70 Hua, Sahashi, Hung, Rigo, Passini, Bennett, Krainer (CR80) 2010; 24 Yang, Patel (CR29) 2019; 29 Lieberman, Shakkottai, Albin (CR57) 2019; 14 Miller, Pestronk, David, Rothstein, Simpson, Appel, Andres, Mahoney, Allred, Alexander (CR72) 2013; 12 Anzalone, Koblan, Liu (CR20) 2020; 38 Mendell, Al-Zaidy, Shell, Arnold, Rodino-Klapac, Prior, Lowes, Alfano, Berry, Church (CR52) 2017; 377 Ying, Zhan, Wang, Yao, Hu, Song, Zhang, Wei, Xiong, Lu (CR68) 2016; 8 Xiao Jie, Hui Ying, Zun Ping, Jin Lian, Li (CR19) 2015; 52 Flotte, Buning (CR50) 2018; 29 Charleston, Schnell, Dworzak, Donoghue, Lewis, Chen, Young, Milici, Voss, DeAlwis (CR14) 2018; 90 Lim, Maruyama, Yokota (CR13) 2017; 11 Karimian, Azizian, Parsian, Rafieian, Shafiei-Irannejad, Kheyrollah, Yousefi, Majidinia, Yousefi (CR21) 2019; 234 Strecker, Jones, Koopal, Schmid-Burgk, Zetsche, Gao, Makarova, Koonin, Zhang (CR28) 2019; 10 Ryu, Koo, Kim, Lim, Baek, Kim, Kim, Kim, Lee, Chung (CR76) 2018; 36 CR9 Acsadi, Love, Jani, Walsh, Gurusinghe, Wolff, Davies (CR46) 1991; 352 CR48 Lin, Chen, Lu, Hong, Hu, Gao, Lai, Li, Wang, Ying (CR22) 2020; 30 Wagner, Amini, Wendering, Burkhardt, Akyüz, Reinke, Volk, Schmueck-Henneresse (CR25) 2019; 25 Song, Jiang, Richter, Rhym, Koblan, Zafra, Schatoff, Doman, Cao, Dow (CR78) 2020; 4 Verdera, Kuranda, Mingozzi (CR63) 2020; 28 CR42 Freije, Myhrvold, Boehm, Lin, Welch, Carter, Metsky, Luo, Abudayyeh, Gootenberg (CR44) 2019; 76 Anzalone, Randolph, Davis, Sousa, Koblan, Levy, Chen, Wilson, Newby, Raguram (CR36) 2019; 576 Zetsche, Gootenberg, Abudayyeh, Slaymaker, Makarova, Essletzbichler, Volz, Joung, van der Oost, Regev (CR27) 2015; 163 CR82 CR81 Alterman, Godinho, Hassler, Ferguson, Echeverria, Sapp, Haraszti, Coles, Conroy, Miller (CR77) 2019; 37 Wu, Lima, Crooke (CR4) 1999; 274 Harper, Staber, He, Eliason, Martins, Mao, Yang, Kotin, Paulson, Davidson (CR59) 2005; 102 Zuo, Sun, Wei, Yuan, Ying, Sun, Yuan, Steinmetz, Li, Yang (CR34) 2019; 364 Sakuma, Barry, Ikeda (CR65) 2012; 443 Goemans (CR8) 2021; 20 Wei, Zhang, Li (CR37) 2017; 39 Kwon (CR16) 2021; 593 Wang, Wu, Shi, Xu, Liu (CR75) 2017; 39 Kolb, Kissel (CR7) 2011; 68 Zhou, Sun, Yan, Liu, Zuo, Gu, Han, Wei, Hu, Zeng (CR31) 2019; 571 CR15 O'Connell, Oakes, Sternberg, East Seletsky, Kaplan, Doudna (CR43) 2014; 516 Davidson, Boudreau (CR56) 2007; 53 Crooke, Witztum, Bennett (CR5) 2018; 27 CR12 CR11 Davidson, Paulson (CR60) 2004; 3 Miller, Cudkowicz, Shaw, Andersen, Atassi, Bucelli, Genge, Glass, Ladha, Ludolph (CR17) 2020; 383 Kemp, Huffnagel, Linthorst, Wanders, Engelen (CR53) 2016; 12 Riboldi, Zanetta, Ranieri, Nizzardo, Simone, Magri, Bresolin, Comi, Corti (CR73) 2014; 50 CR51 Wang, Li, Xiao (CR47) 2000; 97 Zhou, Su, Hu, Zhou, Li, Chen, Xiao, Wang, Wu, Sun (CR45) 2020; 181 Cox, Abudayyeh, Franklin, Kellner, Joung, Zhang (CR41) 2017; 358 Li, Lin, Tang, Lu, Hu, Zuo, Li, Ying, Sun, Lai (CR79) 2020; 7 Choudhury, Hudry, Maguire, Sena-Esteves, Breakefield, Grandi (CR61) 2017; 120 Kabilova, Shmendel, Gladkikh, Chernolovskaya, Markov, Morozova, Maslov, Zenkova (CR67) 2018; 123 Ling, Yang, Hu, Yin, Dai, Qian, Wang, Pan, Hong, Sun (CR70) 2021; 5 Kanasty, Dorkin, Vegas, Anderson (CR58) 2013; 12 Memi, Ntokou, Papangeli (CR18) 2018; 42 Enache, Rendo, Abdusamad, Lam, Davison, Pal, Currimjee, Hess, Pantel, Nag (CR26) 2020; 52 Papastefanaki, Jakovcevski, Poulia, Djogo, Schulz, Martinovic, Ciric, Loers, Vossmeyer, Weller (CR69) 2015; 23 CR24 Lim, Gapinske, Brooks, Woods, Powell, Zeballos, Winter, Perez-Pinera, Gaj (CR33) 2020; 28 Bayever, Iversen, Bishop, Sharp, Tewary, Arneson, Pirruccello, Ruddon, Kessinger, Zon (CR3) 1993; 3 CR62 Tabebordbar, Cheng, Chew, Widrick, Yan, Maesner, Wu, Xiao, Ran, Cong (CR23) 2016; 351 Ralph, Radcliffe, Day, Carthy, Leroux, Lee, Wong, Bilsland, Greensmith, Kingsman (CR74) 2005; 11 Yin, Ling, Wang, Dai, Jiang, Zhou, Paludan, Hong, Cai (CR71) 2021; 39 Palfi, Gurruchaga, Ralph, Lepetit, Lavisse, Buttery, Watts, Miskin, Kelleher, Deeley (CR66) 2014; 383 Farrar, Teoh, Carey, Cairns, Forbes, Herbert, Holland, Jones, Menezes, Morrison (CR10) 2018; 89 Chi, Gatti, Papoian (CR1) 2017; 22 AV Anzalone (2167_CR36) 2019; 576 A Mahas (2167_CR39) 2018; 36 SM Ryu (2167_CR76) 2018; 36 TM Miller (2167_CR72) 2013; 12 A East Seletsky (2167_CR40) 2016; 538 BL Davidson (2167_CR56) 2007; 53 MA Farrar (2167_CR10) 2018; 89 M Ying (2167_CR68) 2016; 8 TR Flotte (2167_CR50) 2018; 29 SJ Kolb (2167_CR7) 2011; 68 F Memi (2167_CR18) 2018; 42 JS Charleston (2167_CR14) 2018; 90 2167_CR38 DL Wagner (2167_CR25) 2019; 25 R Kanasty (2167_CR58) 2013; 12 G Riboldi (2167_CR73) 2014; 50 KR Lim (2167_CR13) 2017; 11 S Jin (2167_CR35) 2019; 364 C Zhou (2167_CR31) 2019; 571 MKS Engelen (2167_CR54) 2012; 7 CF Bennett (2167_CR2) 2021; 61 D Kwon (2167_CR16) 2021; 593 T Sakuma (2167_CR65) 2012; 443 S Palfi (2167_CR66) 2014; 383 D Yin (2167_CR71) 2021; 39 Y Hua (2167_CR80) 2010; 24 2167_CR24 N Goemans (2167_CR8) 2021; 20 CQ Song (2167_CR78) 2020; 4 J Grünewald (2167_CR32) 2019; 37 AP Lieberman (2167_CR57) 2019; 14 HC Verdera (2167_CR63) 2020; 28 SQ Harper (2167_CR59) 2005; 102 2167_CR62 CF Bennett (2167_CR6) 2019; 70 OM Enache (2167_CR26) 2020; 52 L Xiao Jie (2167_CR19) 2015; 52 H Zhou (2167_CR45) 2020; 181 JL Shirley (2167_CR64) 2020; 28 TO Kabilova (2167_CR67) 2018; 123 H Wu (2167_CR4) 1999; 274 ST Crooke (2167_CR5) 2018; 27 S Ling (2167_CR70) 2021; 5 2167_CR9 2167_CR15 MR O'Connell (2167_CR43) 2014; 516 JZ Wang (2167_CR75) 2017; 39 F Eichler (2167_CR55) 2017; 377 2167_CR11 T Miller (2167_CR17) 2020; 383 X Lin (2167_CR22) 2020; 30 2167_CR12 JJ Li (2167_CR79) 2020; 7 F Papastefanaki (2167_CR69) 2015; 23 2167_CR51 DBTGJ Cox (2167_CR41) 2017; 358 E Bayever (2167_CR3) 1993; 3 B Wang (2167_CR47) 2000; 97 JF Alterman (2167_CR77) 2019; 37 H Yang (2167_CR29) 2019; 29 E Zuo (2167_CR34) 2019; 364 Y Wei (2167_CR37) 2017; 39 CA Freije (2167_CR44) 2019; 76 J Strecker (2167_CR28) 2019; 10 JH Hu (2167_CR30) 2018; 556 GS Ralph (2167_CR74) 2005; 11 CKW Lim (2167_CR33) 2020; 28 C Le Guiner (2167_CR49) 2017; 8 2167_CR48 2167_CR42 B Zetsche (2167_CR27) 2015; 163 SR Choudhury (2167_CR61) 2017; 120 2167_CR82 JR Mendell (2167_CR52) 2017; 377 S Kemp (2167_CR53) 2016; 12 AV Anzalone (2167_CR20) 2020; 38 2167_CR81 A Karimian (2167_CR21) 2019; 234 BL Davidson (2167_CR60) 2004; 3 MZK Tabebordbar (2167_CR23) 2016; 351 X Chi (2167_CR1) 2017; 22 GDG Acsadi (2167_CR46) 1991; 352
References_xml	– volume: 377 start-page: 1713 issue: 18 year: 2017 end-page: 1722 ident: CR52 article-title: Single-dose gene-replacement therapy for spinal muscular atrophy publication-title: N Engl J Med – volume: 556 start-page: 57 year: 2018 end-page: 63 ident: CR30 article-title: Evolved Cas9 variants with broad PAM compatibility and high DNA specificity publication-title: Nature – volume: 571 start-page: 275 year: 2019 end-page: 278 ident: CR31 article-title: Off-target RNA mutation induced by DNA base editing and its elimination by mutagenesis publication-title: Nature – volume: 3 start-page: 145 year: 2004 end-page: 149 ident: CR60 article-title: Molecular medicine for the brain: silencing of disease genes with RNA interference publication-title: Lancet Neurol – volume: 36 start-page: 536 issue: 6 year: 2018 end-page: 539 ident: CR76 article-title: Adenine base editing in mouse embryos and an adult mouse model of Duchenne muscular dystrophy publication-title: Nat Biotechnol – volume: 443 start-page: 603 year: 2012 end-page: 618 ident: CR65 article-title: Lentiviral vectors: basic to translational publication-title: Biochem J – volume: 12 start-page: 435 issue: 5 year: 2013 end-page: 442 ident: CR72 article-title: An antisense oligonucleotide against SOD1 delivered intrathecally for patients with SOD1 familial amyotrophic lateral sclerosis: a phase 1, randomised, first-in-man study publication-title: Lancet Neurol – volume: 163 start-page: 759 year: 2015 end-page: 771 ident: CR27 article-title: Cpf1 is a single RNA-guided endonuclease of a class 2 CRISPR-Cas system publication-title: Cell – ident: CR51 – volume: 274 start-page: 28270 year: 1999 end-page: 28278 ident: CR4 article-title: Properties of cloned and expressed human RNase H1 publication-title: J Biol Chem – ident: CR12 – volume: 516 start-page: 263 year: 2014 end-page: 266 ident: CR43 article-title: Programmable RNA recognition and cleavage by CRISPR/Cas9 publication-title: Nature – volume: 39 start-page: 547 issue: 7 year: 2017 end-page: 556 ident: CR75 article-title: The AAV-mediated and RNA-guided CRISPR/Cas9 system for gene therapy of DMD and BMD publication-title: Brain Dev – volume: 89 start-page: 937 year: 2018 end-page: 942 ident: CR10 article-title: Nusinersen for SMA: expanded access programme publication-title: J Neurol Neurosurg Psychiatry – volume: 377 start-page: 1630 year: 2017 end-page: 1638 ident: CR55 article-title: Hematopoietic stem-cell gene therapy for cerebral adrenoleukodystrophy publication-title: N Engl J Med – volume: 68 start-page: 979 year: 2011 end-page: 984 ident: CR7 article-title: Spinal muscular atrophy: a timely review publication-title: Arch Neurol – volume: 5 start-page: 144 year: 2021 end-page: 156 ident: CR70 article-title: Lentiviral delivery of co-packaged Cas9 mRNA and a Vegfa-targeting guide RNA prevents wet age-related macular degeneration in mice publication-title: Nat Biomed Eng – volume: 53 start-page: 781 year: 2007 end-page: 788 ident: CR56 article-title: RNA interference: a tool for querying nervous system function and an emerging therapy publication-title: Neuron – volume: 123 start-page: 59 year: 2018 end-page: 70 ident: CR67 article-title: Targeted delivery of nucleic acids into xenograft tumors mediated by novel folate-equipped liposomes publication-title: Eur J Pharm Biopharm – volume: 364 start-page: 292 year: 2019 end-page: 295 ident: CR35 article-title: Cytosine, but not adenine, base editors induce genome-wide off-target mutations in rice publication-title: Science – ident: CR42 – volume: 50 start-page: 721 issue: 3 year: 2014 end-page: 732 ident: CR73 article-title: Antisense oligonucleotide therapy for the treatment of C9ORF72 ALS/FTD diseases publication-title: Mol Neurobiol – volume: 28 start-page: 709 year: 2020 end-page: 722 ident: CR64 article-title: Immune responses to viral gene therapy vectors publication-title: Mol Ther – volume: 3 start-page: 383 year: 1993 end-page: 390 ident: CR3 article-title: Systemic administration of a phosphorothioate oligonucleotide with a sequence complementary to p53 for acute myelogenous leukemia and myelodysplastic syndrome: initial results of a phase I trial publication-title: Antisense Res Dev – volume: 27 start-page: 714 year: 2018 end-page: 739 ident: CR5 article-title: RNA-targeted therapeutics publication-title: Cell Metab – volume: 52 start-page: 289 issue: 5 year: 2015 end-page: 296 ident: CR19 article-title: CRISPR-Cas9: a new and promising player in gene therapy publication-title: J Med Genet – volume: 4 start-page: 125 issue: 1 year: 2020 end-page: 130 ident: CR78 article-title: Adenine base editing in an adult mouse model of tyrosinaemia publication-title: Nat Biomed Eng – ident: CR15 – volume: 29 start-page: 345 year: 2019 end-page: 346 ident: CR29 article-title: CasX: a new and small CRISPR gene-editing protein publication-title: Cell Res – volume: 39 start-page: 567 year: 2021 end-page: 577 ident: CR71 article-title: Targeting herpes simplex virus with CRISPR-Cas9 cures herpetic stromal keratitis in mice publication-title: Nat Biotechnol – volume: 358 start-page: 1019 year: 2017 end-page: 1027 ident: CR41 article-title: RNA editing with CRISPR-Cas13 publication-title: Science – volume: 576 start-page: 149 issue: 7785 year: 2019 end-page: 157 ident: CR36 article-title: Search-and-replace genome editing without double-strand breaks or donor DNA publication-title: Nature – volume: 593 start-page: 180 issue: 7858 year: 2021 ident: CR16 article-title: Failure of genetic therapies for Huntington’s devastates community publication-title: Nature – ident: CR11 – volume: 120 start-page: 63 year: 2017 end-page: 80 ident: CR61 article-title: Viral vectors for therapy of neurologic diseases publication-title: Neuropharmacology – ident: CR9 – volume: 10 start-page: 212 year: 2019 ident: CR28 article-title: Engineering of CRISPR-Cas12b for human genome editing publication-title: Nat Commun – volume: 7 start-page: 51 year: 2012 end-page: 51 ident: CR54 article-title: X-linked adrenoleukodystrophy (X-ALD): clinical presentation and guidelines for diagnosis, follow-up and management publication-title: Orphanet J Rare Dis – volume: 234 start-page: 12267 year: 2019 end-page: 12277 ident: CR21 article-title: CRISPR/Cas9 technology as a potent molecular tool for gene therapy publication-title: J Cell Physiol – volume: 76 start-page: 826 year: 2019 end-page: 837.e11 ident: CR44 article-title: Programmable inhibition and detection of RNA viruses using Cas13 publication-title: Mol Cell – volume: 97 start-page: 13714 issue: 25 year: 2000 end-page: 13719 ident: CR47 article-title: Adeno-associated virus vector carrying human minidystrophin genes effectively ameliorates muscular dystrophy in mdx mouse model publication-title: Proc Natl Acad Sci U S A – volume: 102 start-page: 5820 year: 2005 end-page: 5825 ident: CR59 article-title: RNA interference improves motor and neuropathological abnormalities in a Huntington’s disease mouse model publication-title: Proc Natl Acad Sci U S A – volume: 364 start-page: 289 year: 2019 end-page: 292 ident: CR34 article-title: Cytosine base editor generates substantial off-target single-nucleotide variants in mouse embryos publication-title: Science – ident: CR81 – volume: 14 start-page: 1 year: 2019 end-page: 27 ident: CR57 article-title: Polyglutamine repeats in neurodegenerative diseases publication-title: Annu Rev Pathol – volume: 24 start-page: 1634 issue: 15 year: 2010 end-page: 1644 ident: CR80 article-title: Antisense correction of SMN2 splicing in the CNS rescues necrosis in a type III SMA mouse model publication-title: Genes Dev – volume: 28 start-page: 1177 year: 2020 end-page: 1189 ident: CR33 article-title: Treatment of a mouse model of ALS by in vivo base editing publication-title: Mol Ther – volume: 42 start-page: 487 issue: 8 year: 2018 end-page: 500 ident: CR18 article-title: CRISPR/Cas9 gene-editing: research technologies, clinical applications and ethical considerations publication-title: Semin Perinatol – volume: 538 start-page: 270 year: 2016 end-page: 273 ident: CR40 article-title: Two distinct RNase activities of CRISPR-C2c2 enable guide-RNA processing and RNA detection publication-title: Nature – volume: 8 start-page: 29977 year: 2016 end-page: 29985 ident: CR68 article-title: Liposome-based systemic glioma-targeted drug delivery enabled by all-d peptides publication-title: ACS Appl Mater Interfaces – volume: 29 start-page: 283 issue: 3 year: 2018 end-page: 284 ident: CR50 article-title: Severe toxicity in nonhuman primates and piglets with systemic high-dose administration of adeno-associated virus serotype 9-like vectors: putting patients first publication-title: Hum Gene Ther – volume: 383 start-page: 1138 year: 2014 end-page: 1146 ident: CR66 article-title: Long-term safety and tolerability of ProSavin, a lentiviral vector-based gene therapy for Parkinson’s disease: a dose escalation, open-label, phase 1/2 trial publication-title: The Lancet – volume: 37 start-page: 884 issue: 8 year: 2019 end-page: 894 ident: CR77 article-title: A divalent siRNA chemical scaffold for potent and sustained modulation of gene expression throughout the central nervous system publication-title: Nat Biotechnol – volume: 352 start-page: 815 issue: 6338 year: 1991 end-page: 818 ident: CR46 article-title: Human dystrophin expression in mdx mice after intramuscular injection of DNA constructs publication-title: Nature – volume: 28 start-page: 723 year: 2020 end-page: 746 ident: CR63 article-title: AAV vector immunogenicity in humans: a long journey to successful gene transfer publication-title: Mol Ther – volume: 11 start-page: 533 year: 2017 end-page: 545 ident: CR13 article-title: Eteplirsen in the treatment of Duchenne muscular dystrophy publication-title: Drug Des Devel Ther – volume: 37 start-page: 1041 year: 2019 end-page: 1048 ident: CR32 article-title: CRISPR DNA base editors with reduced RNA off-target and self-editing activities publication-title: Nat Biotechnol – ident: CR82 – volume: 351 start-page: 407 year: 2016 end-page: 411 ident: CR23 article-title: In vivo gene editing in dystrophic mouse muscle and muscle stem cells publication-title: Science – volume: 39 start-page: 1115 year: 2017 end-page: 1121 ident: CR37 article-title: The “new favorite” of gene editing technology-single base editors publication-title: Yi Chuan – volume: 22 start-page: 823 year: 2017 end-page: 833 ident: CR1 article-title: Safety of antisense oligonucleotide and siRNA-based therapeutics publication-title: Drug Discov Today – volume: 61 start-page: 831 year: 2021 end-page: 852 ident: CR2 article-title: Antisense drugs make sense for neurological diseases publication-title: Annu Rev Pharmacol Toxicol – volume: 25 start-page: 242 issue: 2 year: 2019 end-page: 248 ident: CR25 article-title: High prevalence of Streptococcus pyogenes Cas9-reactive T cells within the adult human population publication-title: Nat Med – volume: 23 start-page: 993 year: 2015 end-page: 1002 ident: CR69 article-title: Intraspinal delivery of polyethylene glycol-coated gold nanoparticles promotes functional recovery after spinal cord injury publication-title: Mol Ther – volume: 12 start-page: 967 year: 2013 end-page: 977 ident: CR58 article-title: Delivery materials for siRNA therapeutics publication-title: Nat Mater – volume: 52 start-page: 662 year: 2020 end-page: 668 ident: CR26 article-title: Cas9 activates the p53 pathway and selects for p53-inactivating mutations publication-title: Nat Genet – volume: 30 start-page: 548 year: 2020 end-page: 550 ident: CR22 article-title: Base editing-mediated splicing correction therapy for spinal muscular atrophy publication-title: Cell Res – ident: CR48 – volume: 181 start-page: 590 year: 2020 end-page: 603.e16 ident: CR45 article-title: Glia-to-neuron conversion by CRISPR-CasRx alleviates symptoms of neurological disease in mice publication-title: Cell – ident: CR38 – volume: 36 start-page: 295 year: 2018 end-page: 310 ident: CR39 article-title: Harnessing CRISPR/Cas systems for programmable transcriptional and post-transcriptional regulation publication-title: Biotechnol Adv – volume: 38 start-page: 824 issue: 7 year: 2020 end-page: 844 ident: CR20 article-title: Genome editing with CRISPR-Cas nucleases, base editors, transposases and prime editors publication-title: Nat Biotechnol – volume: 20 start-page: 251 year: 2021 end-page: 252 ident: CR8 article-title: Gene therapy for spinal muscular atrophy: hope and caution publication-title: Lancet Neurol – volume: 90 start-page: e2146 issue: 24 year: 2018 end-page: e2154 ident: CR14 article-title: Eteplirsen treatment for Duchenne muscular dystrophy: exon skipping and dystrophin production publication-title: Neurology – volume: 383 start-page: 109 issue: 2 year: 2020 end-page: 119 ident: CR17 article-title: Phase 1–2 trial of antisense oligonucleotide Tofersen for SOD1 ALS publication-title: N Engl J Med – volume: 7 start-page: 92 issue: 1 year: 2020 end-page: 101 ident: CR79 article-title: Disruption of splicing-regulatory elements using CRISPR/Cas9 to rescue spinal muscular atrophy in human iPSCs and mice publication-title: Natl Sci Rev – volume: 8 start-page: 16105 year: 2017 ident: CR49 article-title: Long-term microdystrophin gene therapy is effective in a canine model of Duchenne muscular dystrophy publication-title: Nat Commun – volume: 70 start-page: 307 year: 2019 end-page: 321 ident: CR6 article-title: Therapeutic antisense oligonucleotides are coming of age publication-title: Annu Rev Med – ident: CR62 – volume: 12 start-page: 606 issue: 10 year: 2016 end-page: 615 ident: CR53 article-title: Adrenoleukodystrophy - neuroendocrine pathogenesis and redefinition of natural history publication-title: Nat Rev Endocrinol – ident: CR24 – volume: 11 start-page: 429 issue: 4 year: 2005 end-page: 433 ident: CR74 article-title: Silencing mutant SOD1 using RNAi protects against neurodegeneration and extends survival in an ALS model publication-title: Nat Med – ident: 2167_CR9 doi: 10.1016/S0140-6736(16)31408-8 – ident: 2167_CR42 doi: 10.1016/j.cell.2018.02.033 – volume: 22 start-page: 823 year: 2017 ident: 2167_CR1 publication-title: Drug Discov Today doi: 10.1016/j.drudis.2017.01.013 – volume: 383 start-page: 109 issue: 2 year: 2020 ident: 2167_CR17 publication-title: N Engl J Med doi: 10.1056/NEJMoa2003715 – volume: 42 start-page: 487 issue: 8 year: 2018 ident: 2167_CR18 publication-title: Semin Perinatol doi: 10.1053/j.semperi.2018.09.003 – volume: 23 start-page: 993 year: 2015 ident: 2167_CR69 publication-title: Mol Ther doi: 10.1038/mt.2015.50 – volume: 351 start-page: 407 year: 2016 ident: 2167_CR23 publication-title: Science doi: 10.1126/science.aad5177 – volume: 29 start-page: 345 year: 2019 ident: 2167_CR29 publication-title: Cell Res doi: 10.1038/s41422-019-0165-4 – volume: 576 start-page: 149 issue: 7785 year: 2019 ident: 2167_CR36 publication-title: Nature doi: 10.1038/s41586-019-1711-4 – volume: 97 start-page: 13714 issue: 25 year: 2000 ident: 2167_CR47 publication-title: Proc Natl Acad Sci U S A doi: 10.1073/pnas.240335297 – volume: 358 start-page: 1019 year: 2017 ident: 2167_CR41 publication-title: Science doi: 10.1126/science.aaq0180 – volume: 571 start-page: 275 year: 2019 ident: 2167_CR31 publication-title: Nature doi: 10.1038/s41586-019-1314-0 – volume: 39 start-page: 567 year: 2021 ident: 2167_CR71 publication-title: Nat Biotechnol doi: 10.1038/s41587-020-00781-8 – volume: 52 start-page: 662 year: 2020 ident: 2167_CR26 publication-title: Nat Genet doi: 10.1038/s41588-020-0623-4 – volume: 377 start-page: 1713 issue: 18 year: 2017 ident: 2167_CR52 publication-title: N Engl J Med doi: 10.1056/NEJMoa1706198 – volume: 27 start-page: 714 year: 2018 ident: 2167_CR5 publication-title: Cell Metab doi: 10.1016/j.cmet.2018.03.004 – volume: 89 start-page: 937 year: 2018 ident: 2167_CR10 publication-title: J Neurol Neurosurg Psychiatry doi: 10.1136/jnnp-2017-317412 – ident: 2167_CR48 doi: 10.1001/jamaneurol.2020.1484 – volume: 76 start-page: 826 year: 2019 ident: 2167_CR44 publication-title: Mol Cell doi: 10.1016/j.molcel.2019.09.013 – volume: 20 start-page: 251 year: 2021 ident: 2167_CR8 publication-title: Lancet Neurol doi: 10.1016/S1474-4422(21)00071-5 – volume: 383 start-page: 1138 year: 2014 ident: 2167_CR66 publication-title: The Lancet doi: 10.1016/S0140-6736(13)61939-X – volume: 24 start-page: 1634 issue: 15 year: 2010 ident: 2167_CR80 publication-title: Genes Dev doi: 10.1101/gad.1941310 – volume: 4 start-page: 125 issue: 1 year: 2020 ident: 2167_CR78 publication-title: Nat Biomed Eng doi: 10.1038/s41551-019-0357-8 – volume: 8 start-page: 29977 year: 2016 ident: 2167_CR68 publication-title: ACS Appl Mater Interfaces doi: 10.1021/acsami.6b10146 – volume: 37 start-page: 884 issue: 8 year: 2019 ident: 2167_CR77 publication-title: Nat Biotechnol doi: 10.1038/s41587-019-0205-0 – volume: 274 start-page: 28270 year: 1999 ident: 2167_CR4 publication-title: J Biol Chem doi: 10.1074/jbc.274.40.28270 – volume: 10 start-page: 212 year: 2019 ident: 2167_CR28 publication-title: Nat Commun doi: 10.1038/s41467-018-08224-4 – volume: 8 start-page: 16105 year: 2017 ident: 2167_CR49 publication-title: Nat Commun doi: 10.1038/ncomms16105 – ident: 2167_CR51 doi: 10.1016/j.pharmthera.2019.107453 – volume: 68 start-page: 979 year: 2011 ident: 2167_CR7 publication-title: Arch Neurol doi: 10.1001/archneurol.2011.74 – volume: 53 start-page: 781 year: 2007 ident: 2167_CR56 publication-title: Neuron doi: 10.1016/j.neuron.2007.02.020 – volume: 11 start-page: 429 issue: 4 year: 2005 ident: 2167_CR74 publication-title: Nat Med doi: 10.1038/nm1205 – ident: 2167_CR81 doi: 10.1371/journal.pbio.0050073 – volume: 3 start-page: 383 year: 1993 ident: 2167_CR3 publication-title: Antisense Res Dev doi: 10.1089/ard.1993.3.383 – ident: 2167_CR12 doi: 10.1016/S1474-4422(09)70272-8 – ident: 2167_CR24 doi: 10.1038/mtna.2016.58 – volume: 556 start-page: 57 year: 2018 ident: 2167_CR30 publication-title: Nature doi: 10.1038/nature26155 – volume: 181 start-page: 590 year: 2020 ident: 2167_CR45 publication-title: Cell doi: 10.1016/j.cell.2020.03.024 – volume: 29 start-page: 283 issue: 3 year: 2018 ident: 2167_CR50 publication-title: Hum Gene Ther doi: 10.1089/hum.2018.021 – volume: 28 start-page: 709 year: 2020 ident: 2167_CR64 publication-title: Mol Ther doi: 10.1016/j.ymthe.2020.01.001 – volume: 39 start-page: 547 issue: 7 year: 2017 ident: 2167_CR75 publication-title: Brain Dev doi: 10.1016/j.braindev.2017.03.024 – volume: 163 start-page: 759 year: 2015 ident: 2167_CR27 publication-title: Cell doi: 10.1016/j.cell.2015.09.038 – volume: 90 start-page: e2146 issue: 24 year: 2018 ident: 2167_CR14 publication-title: Neurology doi: 10.1212/WNL.0000000000005680 – volume: 377 start-page: 1630 year: 2017 ident: 2167_CR55 publication-title: N Engl J Med doi: 10.1056/NEJMoa1700554 – volume: 593 start-page: 180 issue: 7858 year: 2021 ident: 2167_CR16 publication-title: Nature doi: 10.1038/d41586-021-01177-7 – volume: 516 start-page: 263 year: 2014 ident: 2167_CR43 publication-title: Nature doi: 10.1038/nature13769 – volume: 364 start-page: 289 year: 2019 ident: 2167_CR34 publication-title: Science doi: 10.1126/science.aav9973 – volume: 30 start-page: 548 year: 2020 ident: 2167_CR22 publication-title: Cell Res doi: 10.1038/s41422-020-0304-y – volume: 3 start-page: 145 year: 2004 ident: 2167_CR60 publication-title: Lancet Neurol doi: 10.1016/S1474-4422(04)00678-7 – volume: 14 start-page: 1 year: 2019 ident: 2167_CR57 publication-title: Annu Rev Pathol doi: 10.1146/annurev-pathmechdis-012418-012857 – volume: 234 start-page: 12267 year: 2019 ident: 2167_CR21 publication-title: J Cell Physiol doi: 10.1002/jcp.27972 – volume: 364 start-page: 292 year: 2019 ident: 2167_CR35 publication-title: Science doi: 10.1126/science.aaw7166 – ident: 2167_CR11 doi: 10.1056/NEJMoa1702752 – volume: 37 start-page: 1041 year: 2019 ident: 2167_CR32 publication-title: Nat Biotechnol doi: 10.1038/s41587-019-0236-6 – volume: 102 start-page: 5820 year: 2005 ident: 2167_CR59 publication-title: Proc Natl Acad Sci U S A doi: 10.1073/pnas.0501507102 – volume: 12 start-page: 435 issue: 5 year: 2013 ident: 2167_CR72 publication-title: Lancet Neurol doi: 10.1016/S1474-4422(13)70061-9 – volume: 38 start-page: 824 issue: 7 year: 2020 ident: 2167_CR20 publication-title: Nat Biotechnol doi: 10.1038/s41587-020-0561-9 – volume: 36 start-page: 295 year: 2018 ident: 2167_CR39 publication-title: Biotechnol Adv doi: 10.1016/j.biotechadv.2017.11.008 – volume: 5 start-page: 144 year: 2021 ident: 2167_CR70 publication-title: Nat Biomed Eng doi: 10.1038/s41551-020-00656-y – volume: 70 start-page: 307 year: 2019 ident: 2167_CR6 publication-title: Annu Rev Med doi: 10.1146/annurev-med-041217-010829 – volume: 123 start-page: 59 year: 2018 ident: 2167_CR67 publication-title: Eur J Pharm Biopharm doi: 10.1016/j.ejpb.2017.11.010 – volume: 120 start-page: 63 year: 2017 ident: 2167_CR61 publication-title: Neuropharmacology doi: 10.1016/j.neuropharm.2016.02.013 – ident: 2167_CR62 doi: 10.1002/cpmo.58 – volume: 36 start-page: 536 issue: 6 year: 2018 ident: 2167_CR76 publication-title: Nat Biotechnol doi: 10.1038/nbt.4148 – volume: 52 start-page: 289 issue: 5 year: 2015 ident: 2167_CR19 publication-title: J Med Genet doi: 10.1136/jmedgenet-2014-102968 – ident: 2167_CR15 doi: 10.1056/NEJMoa1900907 – volume: 7 start-page: 92 issue: 1 year: 2020 ident: 2167_CR79 publication-title: Natl Sci Rev doi: 10.1093/nsr/nwz131 – volume: 39 start-page: 1115 year: 2017 ident: 2167_CR37 publication-title: Yi Chuan – volume: 61 start-page: 831 year: 2021 ident: 2167_CR2 publication-title: Annu Rev Pharmacol Toxicol doi: 10.1146/annurev-pharmtox-010919-023738 – volume: 28 start-page: 1177 year: 2020 ident: 2167_CR33 publication-title: Mol Ther doi: 10.1016/j.ymthe.2020.01.005 – volume: 538 start-page: 270 year: 2016 ident: 2167_CR40 publication-title: Nature doi: 10.1038/nature19802 – volume: 352 start-page: 815 issue: 6338 year: 1991 ident: 2167_CR46 publication-title: Nature doi: 10.1038/352815a0 – volume: 12 start-page: 606 issue: 10 year: 2016 ident: 2167_CR53 publication-title: Nat Rev Endocrinol doi: 10.1038/nrendo.2016.90 – volume: 28 start-page: 723 year: 2020 ident: 2167_CR63 publication-title: Mol Ther doi: 10.1016/j.ymthe.2019.12.010 – volume: 25 start-page: 242 issue: 2 year: 2019 ident: 2167_CR25 publication-title: Nat Med doi: 10.1038/s41591-018-0204-6 – volume: 12 start-page: 967 year: 2013 ident: 2167_CR58 publication-title: Nat Mater doi: 10.1038/nmat3765 – volume: 50 start-page: 721 issue: 3 year: 2014 ident: 2167_CR73 publication-title: Mol Neurobiol doi: 10.1007/s12035-014-8724-7 – volume: 7 start-page: 51 year: 2012 ident: 2167_CR54 publication-title: Orphanet J Rare Dis doi: 10.1186/1750-1172-7-51 – volume: 443 start-page: 603 year: 2012 ident: 2167_CR65 publication-title: Biochem J doi: 10.1042/BJ20120146 – ident: 2167_CR38 doi: 10.1126/science.aaf5573 – ident: 2167_CR82 doi: 10.1126/science.1171242 – volume: 11 start-page: 533 year: 2017 ident: 2167_CR13 publication-title: Drug Des Devel Ther doi: 10.2147/DDDT.S97635
SSID	ssj0017594
Score	2.3999414
SecondaryResourceType	review_article
Snippet	Neurogenetic diseases are neurological conditions with a genetic cause (s). There are thousands of neurogenetic diseases, and most of them are incurable. The...
SourceID	proquest pubmed crossref springer
SourceType	Aggregation Database Index Database Enrichment Source Publisher
StartPage	385
SubjectTerms	Antisense oligonucleotides Antisense RNA Bioinformatics Biomedical and Life Sciences Biomedicine Expression vectors Gene therapy Genome editing Human Genetics Internal Medicine Molecular Medicine Review RNA editing RNA-mediated interference
SummonAdditionalLinks	– databaseName: Health & Medical Collection dbid: 7X7 link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfR3LSuRAsPAB4kXWx65xVVrwpo1J-jl7ERVFBD0pzC2kX7CwZNQZD_P3Vnd6IiLrIZd0V9JUddej6wVwXFmUeiU31BjPKG95auRu6ShIybULVqUSG_cP8vaJ343FOF-4TXNY5YInJkbtJjbekZ_VEhlpyWpVnT-_0Ng1KnpXcwuNZViNpctiSJcaDwYXSsbUCBEtGEkRUOakmZQ6l3xCNAYo4IPMYv5ZMH3RNr94SpMAuvkBG1lzJBc9qTdhyXdbsHaffePbcHnRu_On5G9HcFt40udWzQnqpSTVrYxvEZpkr8z0D2mJQVs5kD6DZQeebq4fr25p7pBALVNiRoNitXBSCy9Kxxm3FsWNQnu3rYzXwgXJ7Mio1krW6lZaa0MZZDAiKO2Eq9hPWOkmnd8FYoSpla6U5oFz7kttrHWcO40DDKVcAdUCPY3N5cNjF4t_zVD4OKG0QXQ2CaXNvICTAea5L57x7ez9BdabfJCmzQfZCzgahvEIRL9G2_nJW5xTRisYNaECfvXUGn7HYsV8PtIFnC7I9_Hx_69l7_u1_Ib1OqZBpFi0fViZvb75A1ROZuYw7cB3WxTdLQ priority: 102 providerName: ProQuest
Title	Advances in gene therapy for neurogenetic diseases: a brief review
URI	https://link.springer.com/article/10.1007/s00109-021-02167-y https://www.ncbi.nlm.nih.gov/pubmed/34837498 https://www.proquest.com/docview/2628403271 https://www.proquest.com/docview/2604020317
Volume	100
hasFullText	1
inHoldings	1
isFullTextHit
isPrint
link	http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwlV1La9tAEB6aGEIuIWmaVHmYLeSWCCTt07nZxa5piSmlBucktKtdCBQ5xM7B_z6zq0cIbgo9CIH2ITEzq5nhmwfAVWpQ6yVMx1pbGrOChUbuJh44IZgqnZGhxMbdTEzn7PuCL5qksFUb7d5CkuFP3SW7BRQn9iEFeOHx3uxAj3vfHaV4ng077EDy0P4Q_RYRZ-gONKkyf9_jrTrasjG38NGgdiaHcNDYi2RYM_gIPtjqI-zdNYj4MYyGNYi_Ig8VQWGwpM6o2hC0RkmoVumf4mrSYDGrW1IQjR6yI3XeyieYT8a_v07jpi9CbKjk69hJmvFSKG55UjLKjEElI9HLLVJtFS-doGagZWEELVQhjDEuccJp7qQqeZnSE9itlpX9DERznUmVSsUcY8wmShtTMlYqHKCo2yJIW_Lkpika7ntX_Mm7cseBpDmSMw8kzTcRXHdrHuuSGf-cfdFSPW-OzyrPBGrNhCL3IvjSDaPgezSjqOzy2c9JvO-L9k8EpzW3utdRXyefDVQENy37Xjd__1vO_m_6OexnPhkiRKRdwO766dleoomy1n3YkQvZh97w2_2PMd5H49nPX_0gpy9_i96p
linkProvider	Springer Nature
linkToHtml	http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtR3ZahRBsIgbUF_EM5kYtQV90saZ6XMFkUQTNia7iCSQt3H6AkFmY3aD7E_5jVb3HEGCecvDvEwfU1RX1zF1AbwqLEq9nBtqjGeU1zw1crd0HKTk2gWrUomN6UxOTviXU3G6Bn_6XJgYVtnzxMSo3dzGf-TvSomMNGelKj6e_aKxa1T0rvYtNFqyOPSr32iyLT4cfMbzfV2W-3vHnya06ypALVNiSYNipXBSCy9yxxm3Flm0QhuxLozXwgXJ7Nio2kpW61paa0MeZDAiKO2EKxjuewvWOUNTZgTru3uzr98Gv4USqfUi2kySIqiyS9NJyXrJC0VjSAQ-yJ5W_4rCK_rtFd9sEnn79-Fep6uSnZa4HsCabx7C7WnnjX8EuzttAMGC_GgIEqInbTbXiqAmTFKlzPgWV5POD7R4T2pi0DoPpM2ZeQwnN4K9JzBq5o3fBGKEKZUulOaBc-5zbax1nDuNAwzlagZFj57KdgXLY9-Mn9VQajmhtEJ0Vgml1SqDN8Oas7Zcx7Wzt3usV93VXVSXhJbBy2EYL130pNSNn1_EOXm0u1H3ymCjPa3hcyzW6OdjncHb_vguN_8_LFvXw_IC7kyOp0fV0cHs8CncLWMSRoqE24bR8vzCP0PVaGmed_RI4PtNX4G_r2kchw
linkToPdf	http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtR3JThRB9AUxIV6IuNEKWiZ60grdXeuQEAPiBESIB0nm1nZtCQnpGZ0hZn7Nr_NV9UIMgRuHvnQt_fLq1Vv6bQDvCotSL-eGGuMZ5TVPjdwtHQUpuXbBqlRi4_RMHp3zrxMxWYG_fS5MDKvseWJi1G5q4z_ynVIiI81ZqYqd0IVFfD8cf5r9orGDVPS09u00WhI58cs_aL7N944P8azfl-X4y4_PR7TrMEAtU2JBg2KlcFILL3LHGbcW2bVCe7EujNfCBcnsyKjaSlbrWlprQx5kMCIo7YQrGO77AB4qJop4x9RkMPZQKqcmjGg9SYpAyy5hJ6XtJX8UjcER-CCjWv4vFG9ouje8tEn4jR_Deqe1kv2WzDZgxTdPYO2088s_hYP9NpRgTi4agiTpSZvXtSSoE5NUMzO-xdWk8wjNd0lNDNrpgbTZM8_g_F5w9xxWm2njN4EYYUqlC6V54Jz7XBtrHedO4wBDCZtB0aOnsl3p8thB47Iaii4nlFaIziqhtFpm8GFYM2sLd9w5e6vHetVd4nl1TXIZvB2G8fpFn0rd-OlVnJNHCxy1sAxetKc1fI7Fav18pDP42B_f9ea3w_LybljewBoSfvXt-OzkFTwqYzZGConbgtXF7yu_jTrSwrxOxEjg531T_z8QNx9X
openUrl	ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Advances+in+gene+therapy+for+neurogenetic+diseases%3A+a+brief+review&rft.jtitle=Journal+of+molecular+medicine+%28Berlin%2C+Germany%29&rft.au=Xie%2C+Ying-Xuan&rft.au=Lv%2C+Wen-Qi&rft.au=Chen%2C+Yi-Kun&rft.au=Hong%2C+Shunyan&rft.date=2022-03-01&rft.eissn=1432-1440&rft.volume=100&rft.issue=3&rft.spage=385&rft_id=info:doi/10.1007%2Fs00109-021-02167-y&rft_id=info%3Apmid%2F34837498&rft.externalDocID=34837498
thumbnail_l	http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0946-2716&client=summon
thumbnail_m	http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0946-2716&client=summon
thumbnail_s	http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0946-2716&client=summon